

# **EXHIBIT 1**

**SANDBACH DECLARATION  
EXHIBIT 1**

***John Franklin Sandbach, M.D.***

3606 Windsor Road  
Austin, Texas 78703 Phone: (512) 474-7802

Texas Oncology Cancer Center  
6204 Balcones Drive  
Austin, Texas 78731  
Phone: (512) 427-9400  
Fax: (512) 302-1408

**Personal History**

**DATE OF BIRTH:** August 16, 1946  
**PLACE OF BIRTH:** Enid, Oklahoma  
**MARITAL STATUS:** Married  
**NAME OF SPOUSE:** Gene Anne Cox Sandbach  
**CHILDREN:** Emily Jane Sandbach, May 24, 1973  
John Cox Sandbach, February 5, 1976  
Anna Katherine Sandbach, December 12, 1987

**Education and Training History**

**UNDERGRADUATE:** University of Kentucky  
Lexington, Kentucky, 1964-1967  
**MEDICAL:** University of Kentucky, M.D.  
Lexington, Kentucky, 1967-1971  
**INTERNSHIP:** North Carolina Memorial Hospital  
Straight Medicine  
Chapel Hill, N.C., 1971-1972  
**RESIDENCY:** North Carolina Memorial Hospital  
Internal Medicine, Admitting Resident  
Chapel Hill, N.C., 1972-1973  
**FELLOWSHIPS:** North Carolina Memorial Hospital  
Hematology/Oncology  
Chapel Hill, N.C., 1973-1974

**Certification**

Diplomate, National Board of Medical Examiners, 1972  
Diplomate, American Board of Internal Medicine, 1974  
Board Certified, American Board of Internal Medicine, Hematology, 1977  
Board Certified, American Board of Internal Medicine, Medical Oncology, 1979

## **SANDBACH DECLARATION EXHIBIT 1**

### **Licensure**

Texas Medical License (E-8517)  
Colorado Medical License (34454) (inactive)  
North Carolina Medical License (18140) (inactive)  
Virginia Medical License (26553) (inactive)  
Kentucky Medical License (16306) (inactive)  
Drug Enforcement Administration (AS7585360)  
Texas Department of Public Safety (00030785)  
National Cancer Institute – Investigational Drug (07164)

### **Work History**

1971 – 1975 – Fellowship at UNC  
1976 – 1977 – USAF @ Andrews Air Force Base in Maryland  
1977 – 1995 – Austin Diagnostic Clinic  
1994 – Present – Texas Oncology, P.A.

### **Appointments**

#### **MEDICAL STAFF:**

North Carolina Memorial Hospital, Chapel Hill, N.C., 1973-1975

Malcolm Grow Medical Center  
Andrews Air Force Base, Maryland  
Hematologist/Oncologist, 1975-1976

The Austin Diagnostic Clinic, Austin, Texas  
Private Practice of Hematology/Oncology, 1977 to 1995  
Chief of Hematology/Oncology Section, 1986-1988

Holy Cross Hospital, Chief of Medicine  
Austin, Texas, 1978-1979

The Austin Diagnostic Clinic  
Board of Directors, 1989-1994

Texas Oncology, P.A., Partner  
Austin, Texas, 1994 to present

#### **CLINICAL RESEARCH:**

Texas Cancer Center, Director of Research, Austin, Texas 1992 to 1999

Physician Reliance Network Research, General Medical Oncology, Program Director  
1996 – 1998

U.S. Oncology Research, Committee Co-Chair, General Medical Oncology Research  
Committee, 1999 - 2002

U.S. Oncology Research, Committee Vice-Chairman, General Medical Research  
Committee, 2002-present

Texas Oncology P.A., Board of Directors, April 2002 –present

#### **SCIENTIFIC:**

## **SANDBACH DECLARATION EXHIBIT 1**

Consultant, Handbook of Nonprescription Drugs, Fifth Edition

American Pharmaceutical Association, 1977

Consultant, Scientific Publications Committee of Texas Medicine, published by the Texas Medical Association, 1980 to 1996

Consultant, Archives of Internal Medicine, Editorial Review Board, 1985 to 1994

Editorial Board, Investigational New Drugs, 1986 to 1996

American Society of Clinical Oncology Chemotherapy Sensitivity and Resistance Assay Working Group, 2003

Medical Director Genetics Program US Oncology 2009 - present

### **MEDICAL:**

Austin Comprehensive Hospice Program

Board of Directors, 1979 – 1984, 1993 – 1998, Hospice Austin; Physician Advisory Committee, 2000 to present

Medical Imaging Center of Austin

Board of Directors, 1979 – 1984

Chairman of the Board, 1985 – 1988

United Action for the Elderly, Austin, Texas

Board of Directors, 1986 – 1987

PaciCare of Texas/Austin

Chairman, Utilization Review Committee, 1988 – 1989

The Austin Diagnostic Clinic Research Foundation

Board of Directors, 1986 – 1990

Vice Chairman, 1989 – 1990

St. David's Community Hospital, Austin, Texas

Chairman, Pharmacy and Therapeutics Committee, 1984 – 1986

Texas Oncology, P.A.

Medical Oncology Quality Committee, 1996 – present

Texas Oncology, P.A.

Board of Directors, 2002 – present

### **Military History**

Malcolm Grow Medical Center

Major, Andrews AFB, Maryland

Hematology/Oncology Division, 1975 – 1977

### **Teaching Assignments**

The University of Texas Health Science Center at San Antonio

Associate Professor of Medicine, 1982 – 2002

## **SANDBACH DECLARATION EXHIBIT 1**

### **Honors and Awards**

Roche Medical Scholarship, 1970-1971  
Alpha Omega Alpha, 1971  
Outstanding Intern Award, 1972  
Clinical Cancer Training Grant; Public Health Service Grant  
(T12-CA-98114-90) 1973 – 1975  
Health Care Hero-Austin Business Journal, 2006

### **Professional Organizations/Committees**

Alpha Epsilon Delta, 1966  
Alpha Omega Alpha, 1971  
USAF Reserve – Commissioned Officer, 1972  
Associate – American College of Physicians, 1973 – 1975  
Southwestern Oncology Group, 1982 – 2000  
American Medical Association  
Texas Medical Association  
American Cancer Society  
American Society of Clinical Oncology  
Southwestern Oncology Group Breast Committee, 1983 – 1990  
American Society of Clinical Oncology Education Committee, 1983 – 1984  
American Society of Clinical Oncology Scientific Program Committee, 1984 – 1985  
American Society of Clinical Oncology Nominations Committee, 1986  
Austin Comprehensive Hospice Program, Chairman of the Board, 1979 – 1984; member,  
Board of Directors, 1993 – 1998  
Hospice Austin Foundation, 2006-Present

### **Privileges**

#### **ACTIVE STAFF:**

Brackenridge Hospital, Austin, Texas  
Seton Medical Center, Austin, Texas  
Seton Northwest Hospital, Austin, Texas  
St. David's Hospital, Austin, Texas  
Heart Hospital, Austin, Texas  
South Austin Medical Center  
North Austin Medical Center

## SANDBACH DECLARATION EXHIBIT 1

### **Presentations**

Sandbach, J.: Hospice Care, Central Texas Cancer Symposium, Austin, Texas, March 1980

Sandbach, J.: Faculty, 3<sup>rd</sup> Annual Breast Cancer Symposium, University of Texas Health Science Center, San Antonio, Texas, November 1980.

Sandbach, J.: Direct Cloning of Human Breast Cancer in Soft Agar, Plenary Session, American Society of Clinical Oncology and American Association of Cancer Research, 1981.

Sandbach, J.: Guest speaker, Technocracy Ethics: "Live or Let Die" at St. David's Community Hospital. Technocracy Ethics Lecture Series, September 1987.

### **Publications and Publications**

Von Hoff, D.D.; Casper, J.; Bradley, E.; Sandbach, J.; Jones, D.; and Makuch, R.; Association Between Human Tumor Colony-forming Assay Results and Response of an Individual Patient's Tumor to Chemotherapy. American Journal of Medicine, May 1981.

Von Hoff, D.D.; Myers, J.W.; John, J.; Sandbach, J.F.; Pocelindo, R.; Clark, G.; and Coltman, C.A.; Phase I Clinical Investigation of 9,10-AntraCenedicarboxaldehyde BIS (4,5-dihydro-1H-imidazol-2yl) hydrazone dihydrochloride (CL216,942). Cancer Research, Vol. 41, August 1981.

Von Hoff, D.D.; Sandbach, J.F.; Osborne, K.; Metelmann, M.D.; Clark, G.M.; O'Brien, M.D.; and the South Central Human Tumor Cloning Group: Potential and Problems with Growth of Breast Cancer in Human Tumor Cloning System. Breast Cancer Research and Treatment I, 1981.

Sandbach, J., et al.: Direct Cloning of Human Breast Cancer in Soft Agar. Cancer, October 1983.

Von Hoff, D.D.; Clark, G.M.; Stogdill, B.J.; Sarosdy, M.F.; Sandbach, J.F.; and the South Central Texas Cloning Group: A Prospective Trial of a Human Tumor Cloning System. Cancer Research Vol 43: 1926-1931, 1983.

Myers, J.W.; Von Hoff, D.D.; Kuhn, J.G.; Osborne, C.K.; Sandbach, J.F.; Pocelinko, R.; Anaphylactoid Reactions Associated with Bisanthrane Infusions. Investigational New Drugs, 1983.

Osborne, C.K.; Von Hoff, D.D.; Cowan, J.D.; Sandbach, J.F.; Bisanthrane, An Active Drug in Breast Cancer Selected by Screening in the Cloning Assay. Cancer Treatment Reports, Vol 68:2, February 1984.

Mahoney, D.; Steuben, P.; Sandbach, J.; and Fernbach, D.: Extraneural Metastases from Medulloblastoma: Long-Term Survival After Sequentially Scheduled Chemotherapy and Radiotherapy. Medical and Pediatric Oncology, Vol. 14:329-331, 1986.

Von Hoff, D.D.; Sandbach, J.F.; Clark, G.M.; Turner, J.; Forseth, B.F.; Piccart, M.J.; Colombo, N.; Muggia, F.M.: Selection of Cancer Chemotherapy for a Patient by an In Vitro Assay Versus a Clinician. Journal of the National Cancer Institute, Vol. 82, No. 2, January 1990.

## SANDBACH DECLARATION EXHIBIT 1

Perez, E.A.; Hesketh, P.; Sandbach, J.; et al: Comparison of Single-Cell Oral Granisetron vs. Intravenous Ondansetron in the Prevention of Nausea and Vomiting Induced by Moderately Emetogenic Chemotherapy: A Multi-Center Double-Blinded Randomized Parallel Study, American Society of Oncology, 1997 (submitted for publication).

Rothenberg, M.; Cox, J.; DeVore, R.; Sandbach, J.; et al: A Multicenter, Phase II Trial of Weekly Irinotecan (CPT-11) in Patients with Previously Treated Colorectal Cancer, Journal of Clinical Oncology, 2001.

Hughesdon, M., and Sandbach, J.: Nurse Oncologist Utilization in a Hematology/Oncology Clinic. American Col. Phys. – Soc. Of Air Force Phys., Williamsburg, Virginia, 1977.

Sandbach, J.; Steinfeld, A.; Schwamm, H.; and Bernard, D.: A formerly Unreported Presentation of Hodgkin's Disease. Amer. Col. Phys. – Society of Air Force Physicians, Williamsburg, Virginia 1977.

Sandbach, J., et al: Assay for Clonogenic Cells in Human Breast Cancer. American Association Clinical Research, San Diego, California, 1980 (Abstract 557).

Sandbach, J.F.; O'Brien, M.D.; Cruz, A.; Clark, G.; Von Hoff, D.D.; and The South Texas Human Tumor Cloning Group. Directed Cloning of Human Breast Cancer in Soft Agar. American Society of Clinical Oncology, 1981 (Abstract C-71).

Von Hoff, D.D.; Sandbach, J.F.; Osborne, D.K.; Metelman, C.; Clark, G.M.: Growth of Human Breast Cancer in a Human Tumor Cloning System. NCI-EORTA Meeting, Brussels, Belgium, October 1981.

Von Hoff, D.D.; Myers, J.W.; Kuhn, J.; Osborne, C.K.; Sandbach, J.F.; Coltman, C.A.: Phase I and II Trials with Bisanthrane Hydrochloride (BIS). NCI-EORTA Meeting, Brussels, Belgium, October 1981.

Von Hoff, D.D.; Clark, G.A.; Sarosdy, M.; Stogdill, B.; Sandbach, J.F.: Clinical Correlations for a Human Tumor Cloning System. NCI-EORTA Meeting, Brussels, Belgium, October 1981.

Myers, J.W.; Von Hoff, D.D.; Kuhn, J.; Sandbach, J.F.; Pocelinko, R.; Clark, G.; Coltman, C.; and Rodriguez, V.: Phase I Investigation of CL216942 on a Single Dose Intermittent Schedule. American Association of Cancer Research, 1981 (Abstract 689).

Osborne, C.K.; Von Hoff, D.D.; and Sandbach, J.F.: Activity of Bisanthrane in a Phase II Study in Advanced Breast Cancer. ASCO Proceedings, 1982 (Abstract C-336).

Osborne, K.D.; Von Hoff, D.D.; Clark, G.M.; Sandbach, J.F.; O'Brien, M.; and The South Central Texas Human Tumor Cloning Group: The Clonogenic Assay Identified Antagonism in Combination Chemotherapy of Breast Cancer. American Association of Clinical Research, April, 1982 (Abstract 729).

Sandbach, J.F.; Osborne, K.; Von Hoff, D.; Cohen, S.; Gorden, D.; Mims, C.; Ellis, B.; Oines, D.; Whitecon, J.; and Cowan, J.: Bisanthrane, an Active Drug in Breast Cancer Selected by Screening in the Cloning Assay, The 5<sup>th</sup> Annual Breast Cancer Symposium, 1982 (Abstract 63).

Cowan, J.D.; Sandbach, J.F.; Von Hoff, D.D.; and Clark, G.M.: The Comparative Antitumor Activity of Adriamycin, Mitoxanthrone and Bisanthrane in Human Breast

## SANDBACH DECLARATION EXHIBIT 1

Cancers as Measured by the Cloning Assay, The 5<sup>th</sup> Annual Breast Cancer Symposium, 1982 (Abstract 38).

Kampe, C.E.; Rodgers, G.P.; Oswalt, J.D.; and Sandbach, J.F.: Exercise-induced Fragmentation Hemolysis: A Simple in Vivo Test to Evaluate Heart Valve Hemolysis, The Southern Medical Journal, 1998 (in press).

Weissman, C.; Sandbach, J.F.; Brooker, R.; Ilegbodu, D.; Bell, S.; Asmar, L.: Phase II Study of Weekly Concomitant Taxotere/Carboplatin in Stage IIIB, With Effusion or Stage IV Non Small Cell Lung Cancer Patients Who are < or = Age 65 and Performance Status 2. U.S. Oncology, Houston, Texas. USA.

David Loesch, M.D.; F. Anthony Greco, M.D., Joyce O'Shaughnessy, M.D.; Nicholas Robert, M.D.; Neil N. Senzer, M.D.; Howard A. Burris, M.D.; John D. Hainsworth, M.D.; Sasha Vukelja, M.D.; John Sandbach, M.D.; Frankie Holmes, M.D.; Scot Sedlacek, M.D.; Deborah Lindquist, M.D.; Kristi A. Boehm, M.D.; Feng Zhan, Ph.D.; Lina Asmar, Ph.D. A randomized, multicenter phase III trial comparing regimens of doxorubicin + cyclophosphamide followed by paclitaxel or doxorubicin + paclitaxel followed by weekly paclitaxel as adjuvant therapy for patients with high risk breast cancer.

Thomas Cartwright, M.D.; John Cox, M.D.; Marcus Neubauer, M.D.; Andrew D. McCollum, M.D.; John Sandbach, M.D.; Michael A. Monticelli, M.D.; Kristi A. Boehm, M.S.; Des Ilegbodu, DrPh; Lina Asmar, Ph.D. A Phase II study of gemcitabine plus zoledronic acid in Stage IV cancer of the pancreas.

David Loesch, MD<sup>1,2</sup>; F. Anthony Greco, MD<sup>3</sup>; Joyce O'Shaughnessy, MD<sup>1,4</sup>; Nicholas Robert, MD<sup>1,5</sup>; Neil N. Senzer, MD<sup>1,4</sup>; John D. Hainsworth, MD<sup>3</sup>; Sasha Vukelja, MD<sup>1,6</sup>; John Sandbach, MD<sup>1,7</sup>; Frankie Holmes, MD<sup>1,8</sup>; Scot Sedlacek, MD<sup>1,9</sup>; Deborah Lindquist, MD<sup>1,2</sup>; Jario Olivares, MD<sup>1,11</sup>; Kristi A. Boehm, MS<sup>1</sup>; Feng Zhan, PhD<sup>1</sup>; Lina Asmar, PhD<sup>1</sup> A randomized, multicenter phase III trial comparing regimens of doxorubicin + cyclophosphamide followed by paclitaxel or doxorubicin + paclitaxel followed by weekly paclitaxel as adjuvant therapy for patients with high risk breast cancer. ASC Journal of Clinical Oncology, Volume 25, No 18S, June 20, 2007.

Frankie Ann Holmes<sup>1,2</sup>, David Loesch<sup>1,3</sup>, Sasha Vukelja<sup>1,4</sup>, Joanne L Blum<sup>1,5</sup>, Kristi J McIntyre<sup>1</sup>, John E Pippen<sup>1,5</sup>, John Sandbach<sup>1,6</sup>, WJ Hyman, Don A Richards, Kristi Boehm<sup>1</sup>, Lina Asmar<sup>1</sup>, Joyce O'Shaughnessy<sup>1,5</sup>. Are granulocyte colony-stimulating growth factors (CSF's) needed to prevent febrile neutropenia (FN) for course #1 of adjuvant chemotherapy with "standard" doxorubicin-cyclophosphamide (ASC) Results from two consecutive US Oncology community adjuvant trials.

Stephen E Jones, Michael A. Savin, Frankie Ann Holmes, Joyce A. O'Shaughnessy, Joanne L. Blum, Svetislava Vukelja, Kristi J. McIntyre, John E. Pippen, James H. Bordelon, Robert Kirby, John Sandbach, William J. Hyman, Pankaj Khandelwal, Angel G. Negron, Donald A. Richards, Stephen P. Anthony, Robert G. Mennel, Kristi A. Boehm, Walter G. Meyer, Lina Asmar. Phase III Trial Comparing Doxorubicin Plus Cyclophosphamide With Docetaxel Plus Cyclophosphamide As Adjuvant Therapy for Operable Breast Cancer. Journal of Clinical Oncology, Vol 24, No 34, December 1, 2006. (DOI: 10.1200/JCO.2006.06.5391)

Eisenbraun A, Wenstrup R, Fry C, Reid, J, Hellerstedt, B, Sailer, L and Sandbach J Hereditary Breast and Ovarian Cancer Testing Integration and Outcomes within Community Oncology Practices. Submitted